Flexibility by design

Good Clinical Practice Journal

Volumn 13, Issue 7, 2006, Pages 13-17

  Phillips, Allan J ^a  

^a ICON CLINICAL RESEARCH   (United States)

Author keywords

Adaptive allocation; Combining phase II III; Endpoints; Interim analyses; Sample size re estimation

Indexed keywords

ANTINEOPLASTIC AGENT; NEW DRUG;

ANALYTICAL ERROR; ARTICLE; CLINICAL DECISION MAKING; CLINICAL OBSERVATION; CLINICAL STUDY; CLINICAL TRIAL; CONSULTATION; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG DESIGN; DRUG DOSE REGIMEN; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; GOOD CLINICAL PRACTICE; HEALTH CARE ORGANIZATION; HEALTH CARE PLANNING; HUMAN; KNOWLEDGE; META ANALYSIS; METHODOLOGY; POPULATION RESEARCH; POST HOC ANALYSIS; RELIABILITY; SAMPLE SIZE; STATISTICAL ANALYSIS; STATISTICAL PARAMETERS; SYSTEMATIC REVIEW;

EID: 33745776490     PISSN: 13500961     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. AJ Phillips, ON Keene. 'Adaptive design for pivotal trials: Discussion points from the PSI adaptive design expert group', Pharmaceutical Statistics, 5, pp6l-66, 2006.
2. CHMP. Draft Reflection Paper on methodological issues in confirmatory clinical trials with flexible design and analysis plan, 2006 (www.emea.eu.int/pdfs/human/ewp).
3. R Simon. 'Optimal two-stage designs for Phase II clinical trials', Controlled Clinical Trials, 10, pp1-10, 1989.
4. DA Berry, P Mueller, AP Grieve, et al. 'Bayesian designs for dose-ranging drug trials', In: RE Gatsonis, B Kas, A Carlin, et al (eds). Case Studies in Bayesian Statistics, Vol 5, New York: Springer, 2001.
5. AL Gould. 'Sample size re-estimation: recent developments and practical considerations' Statistics in Medicine, 20, pp2625-2643, 2001.
6. M Keiser, T Friede. 'Re-calculating the sample size in internal pilot study designs with control of the type 1 error rate', Statistics in Medicine, 19, pp901-911, 2000.
7. F van Leth, P Phanuphak, K Ruxrungtham, et al. 'Comparison of first-line antiretroviral therapy with regimes including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study', The Lancet, 363, ppl253-1262, 2004.
8. N Stallard, S Todd. 'Sequential designs for Phase III clinical trials incorporating treatment selection', Statistics in Medicine, 22, pp689-703, 2003.
9. PJ Kelly, N Stallard, S Todd. 'An adaptive group sequential design for phase II/III clinical trials that select a single treatment from several', Journal of Biopharmaceutical Statistics, 15, pp641-658, 2005.
10. S Todd, N Stallard. 'A new combined clinical trial design combining phases 2 and 3: Sequential designs with treatment selection and a change of endpoint', Drug Information Journal, 39, pp109-118, 2005.
11. P Bauer, M Kieser. 'Combining different phases in the development of medical treatments within a single trial', Statistics in Medicine, 18, pp1833-1848, 1999.
12. P Royston, MKB Palmar, W Qian. 'Novel designs for multi-arm trials with survival outcomes with an application in ovarian cancer', Statistics in Medicine, 22, pp2239-2256, 2003.
13. ICH E9 Expert Working Group. Statistical Principles for Clinical-Trials: ICH Harmonized Tripartite Guideline. Statistics in Medicine, 18, pp1905-1942, 1999.
14. CS CoCey, KE Muller. 'Exact test size and power of a Gaussian error linear model for an internal pilot study', Statistics in Medicine, 18, pp1199-1214, 1999.
15. EJ Topol, DJ Moliterno, et al. 'Comparison of two platelet glycoprotein IIb/IIIa inhibitors, Trofiban and Abciximab, for the prevention of ischaemic events with percutaneous coronary revascularisation', New England Journal of Medicine, 344, pp1888-1894, 2001.
16. CPMP. Points to Consider: Switching between superiority and non-inferiority, 1999 (www.emea.eu.int/htms/human/ewp/ewpptc.htm).